Idogen AB (“Idogen”) today announces that the company has been awarded funding of 2.9 million Euro from Horizon 2020, the EU Framework Programme for Research and Innovation, for the development of the company’s tolerogenic vaccine for the treatment of patients with severe hemophilia A and inhibitory antibodies against factor VIII.
The EU Horizon 2020 SME Instrument phase II grant runs over 33 months and the overall goal of Idogen’s granted application is to perform preclinical safety studies, establish an in-house production capability for manufacture of the tolerogenic vaccine for clinical studies, and perform the first phase I/IIa study in patients with hemophilia A who have inhibitory factor VIII antibodies. The funding will be paid in tranches during the project’s term.
“We are very grateful and proud to be one of the few chosen in the tough competition for funding from the Horizon 2020, SME Instrument. The fact that EU chooses to fund our project is an important confirmation of the potential of our vaccine technology.” CEO Lars Hedbys comments.
About Horizon 2020 – The EU Framework Programme for Research and Innovation
Horizon 2020 is the biggest EU Research and Innovation programme ever, with nearly 80 billion Euro of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The goal of the programme is to ensure that Europe produces world-class science, removes barriers to innovation, and facilitates for the public and private sectors to work together in delivering innovation. The SME Instrument is aimed at small and medium-sized businesses and allows financing of individual companies. For additional information about Horizon 2020, see https://ec.europa.eu/programmes/horizon2020/.
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 18th of May 2017.
Idogen develops tolerogenic vaccines which re-program the immune system. The term “tolerogenic” refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The treatment method comprises cells from the patient’s blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company’s technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com